US Patent No. 9,963,711

FAD2 PERFORMANCE LOCI AND CORRESPONDING TARGET SITE SPECIFIC BINDING PROTEINS CAPABLE OF INDUCING TARGETED BREAKS


Patent No. 9,963,711
Issue Date May 08, 2018
Title Fad2 Performance Loci And Corresponding Target Site Specific Binding Proteins Capable Of Inducing Targeted Breaks
Inventorship Noel Cogan, Macleod (AU)
John Forster, Diamond Creek (AU)
Matthew Hayden, Templestowe (AU)
Tim Sawbridge, Coburg (AU)
German Spangenberg, Bundoora (AU)
Steven R. Webb, Westfield, IN (US)
Manju Gupta, Carmel, IN (US)
William Michael Ainley, Carmel, IN (US)
Matthew J. Henry, Indianapolis, IN (US)
Jeffrey C. Miller, Richmond, CA (US)
Dmitry Y. Guschin, Richmond, CA (US)
Assignee Sangamo Therapeutics, Inc., Richmond, CA (US) Dow AgroSciences LLC, India...

Claim of US Patent No. 9,963,711

1. A transgenic cell comprising a non-naturally occurring exogenous nucleotide sequence integrated within any of SEQ ID Nos:17-26, 28-33 or 35-38 into an endogenous FAD2A, FAD2A?, FAD2C and/or FAD2C? gene, wherein the non-naturally occurring exogenous nucleotide sequence comprises non-coding sequences comprising a plurality of unique nuclease target sites and two or more expression cassettes separated by the non-coding sequences.